Bharat Biotech, the Covaxin Manufacturer has been submitting data to WHO as per the request of additional info at WHO on 27th September 2021. It has been mentioned that the Vaccine will be cleared of license issues as early as by next week when the UN agency and independent group of experts meet. This has been delayed due to the global body sent more technical queries to its manufacturer, Bharat Biotech.

“WHO & an independent group of experts is scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin,”

In the absence of EUA, Covaxin will not be considered an accepted vaccine by most countries around the world. WHO’s queries for Bharat Biotech came despite the Hyderabad-based drug maker asserting that it has submitted all data required for clearance. According to them, Phase III clinical trials of Covaxin had demonstrated an efficacy rate of 77.8%.

Covishield, manufactured by the Serum Institute of India and developed by researchers at Oxford and AstraZeneca, is the only India-made vaccine on the WHO list now.

Covaxin, along with Covishield, was the vaccine first deployed by India in its massive nationwide inoculation drive against coronavirus launched in January this year. Covaxin, along with Covishield, was the vaccine first deployed by India in its massive nationwide inoculation drive against coronavirus launched in January this year.